Related Experiment Video
Updated: Sep 11, 2025
Quantitative Micro-CT Analysis of Aortopathy in a Mouse Model of β-aminopropionitrile-induced Aortic Aneurysm and Dissection
Published on: July 16, 2018
Mesenteric Artery Dissection Aneurysm Associated with Apatinib in a Prostate Cancer Patient: A Case Report and
Tiejun Ren1, Jinjin Gu1, Dingyi Wang1
1Oncology Special Ward, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, People's Republic of China.
Background:
Apatinib mesylate, a VEGFR2 tyrosine kinase inhibitor, is approved for advanced liver, esophageal, gastric and other malignant tumors, but its adverse effects require attention. We report a 79-year-old male with prostatic adenocarcinoma who developed superior mesenteric artery dissecting aneurysm after combined apatinib and chemotherapy. Apatinib, an anti-angiogenic agent, synergizes with chemotherapy. After informed consent, the combination regimen was initiated. Two cycles later, the patient had tolerable intermittent abdominal pain, and CT confirmed the aneurysm. Due to progressive tumor and poor physical status, no further treatment was given as the aneurysm did not affect the disease course. This case report aims to provide insights into the safe application of apatinib in clinical practice.
Materials And Methods:
The materials for the literature review were gathered through a comprehensive search conducted on PubMed. Which yielded VEGFR2 treated for prostate cancer.
Case Report:
In this case report, a 79-year-old male with a height of 172 cms and a weight of 67 kgs who had been diagnosed with prostate adenocarcinoma for over three years. MRI scan indicated that bone metastases increased and enlarged compared with prior test. No significant abnormalities were observed in both physical and blood examinations. The pelvic MRI scan showed a prostatectomy changes, multiple abnormal signals in the bilateral ilium, acetabulum, femur, ischiatic bone, pubis, sacral vertebrae, and part of the lumbar vertebrae.
Conclusion:
Antiangiogenic agents are being increasingly utilized in clinical practice. As clinicians, it is imperative to remain vigilant against potential complications such as arterial dissection and aneurysm, while conducting meticulous evaluations of associated risks. Notably, this article serves solely as a reference and does not advocate for the adjustment of treatment protocols on this basis.
Insights
Apatinib mesylate, a VEGFR2 inhibitor, is used for advanced cancers. A patient developed a superior mesenteric artery dissecting aneurysm during combination therapy, highlighting potential risks of anti-angiogenic agents.
Area of Science:
- Oncology
- Vascular Surgery
Background:
- Apatinib mesylate, a VEGFR2 tyrosine kinase inhibitor, is approved for advanced cancers.
- Anti-angiogenic agents like apatinib are increasingly used in clinical practice.
- Potential adverse effects of apatinib require careful monitoring.
Observation:
- A 79-year-old male with advanced prostate adenocarcinoma received combination therapy with apatinib and chemotherapy.
- The patient developed intermittent abdominal pain after two cycles of treatment.
- CT scan confirmed a superior mesenteric artery dissecting aneurysm.
Findings:
- The case report details a rare complication of apatinib therapy: dissecting aneurysm.
- The aneurysm did not significantly impact the patient's disease course or tumor progression.
- This case underscores the importance of vigilance for vascular complications during anti-angiogenic therapy.
Implications:
- Clinicians must be aware of the potential for arterial dissection and aneurysm formation with anti-angiogenic agents.
- Meticulous risk evaluation is crucial when prescribing therapies like apatinib.
- This report provides insights for the safe clinical application of apatinib, emphasizing risk-benefit assessment.
Related Concept Videos
01:26Aneurysm III: Interprofessional Care
01:21Aneurysm II: Clinical Manifestations and Diagnostic Studies